
Should paclitaxel be considered an old generation DCB? The limus era
Author(s) -
Gaetano Di Palma,
Erick Sanchez-Jimenez,
Florin-Leontin Lazar,
Bernardo Cortese
Publication year - 2021
Publication title -
reviews in cardiovascular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.555
H-Index - 39
eISSN - 2153-8174
pISSN - 1530-6550
DOI - 10.31083/j.rcm2204138
Subject(s) - paclitaxel , medicine , cath lab , restenosis , sirolimus , safety profile , surgery , stent , intensive care medicine , pharmacology , chemotherapy , adverse effect , myocardial infarction , conventional pci